GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 35 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $284,107 | +205.9% | 98,648 | +304.7% | 0.00% | – |
| Q2 2023 | $92,861 | +101.0% | 24,373 | -1.9% | 0.00% | – |
| Q1 2023 | $46,209 | -9.9% | 24,844 | +11.4% | 0.00% | – |
| Q4 2022 | $51,279 | -92.7% | 22,295 | -89.8% | 0.00% | – |
| Q3 2022 | $705,000 | -76.7% | 219,108 | -60.1% | 0.00% | – |
| Q2 2022 | $3,020,000 | +106.4% | 549,035 | -12.5% | 0.00% | – |
| Q1 2022 | $1,463,000 | -60.0% | 627,793 | +3.6% | 0.00% | – |
| Q4 2021 | $3,660,000 | -72.6% | 606,131 | -37.1% | 0.00% | -100.0% |
| Q3 2021 | $13,362,000 | -0.4% | 963,335 | -6.6% | 0.00% | 0.0% |
| Q2 2021 | $13,413,000 | -5.4% | 1,031,755 | +12.0% | 0.00% | 0.0% |
| Q1 2021 | $14,184,000 | – | 921,030 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |